Oncology Solutions
ImpediMed’s point-of-care oncology solutions can help you deliver targeted, personalized, care to your patients.
81% Lower Rate of Chronic Cancer-Related Lymphedema
Chirag Shah, MD, April Zambelli-Weiner, Nicole Delgado, Ashley Sier, Robert Bauserman, Jerrod Nelms
This meta‑analysis comparing bioimpedance spectroscopy versus circumferential measurement includes:
- 50 lymphedema studies and over 67,000 patients studied
- Investigated BCRL in breast cancer patients
- Analyzed impact of prospective monitoring and intervention
Study Findings
Results of meta-analysis comparing the use of Bioimpedance Spectroscopy vs. Circumferential Measurement (tape measure) and Impact of Prospective Monitoring and Intervention for Lymphedema.
81% Lower Rate of Chronic Lymphedema than Circumference Monitoring
This recent meta-analysis confirms that routine monitoring for early detection of lymphedema using ImpediMed’s L-Dex® technology, combined with early intervention, cuts the relative rate of chronic breast cancer-related lymphedema by 81% when compared to circumference monitoring.
Reduced Rates of Chronic Lymphedema in Short-Term and Long-Term Follow-up
This recent meta-analysis confirms that routine monitoring for early detection of lymphedema using ImpediMed’s L-Dex® technology, combined with early intervention, cuts the relative rate of chronic breast cancer-related lymphedema by 81% when compared to circumference monitoring.
Reduced Rates of Chronic Lymphedema in High-Risk Patients
The benefit is sustained in high-risk subgroups as well as short-term and long-term follow-up. L-Dex monitoring and intervention studies showed a statistically significant reduction in chronic lymphedema in studies with >50% axillary lymph node dissection (ALND), >40% mastectomy, <2 years follow-up, and>2 years follow-up when compared to circumference studies.
Clinical Practice Guidelines
NCCN Guidelines® recommend patient education and regular monitoring for the early detection of lymphedema.
Additional guidelines support early detection and intervention
Testing for Early Lymphedema is Easy
L-Dex® testing with the
SOZO® Digital Health Platform
- Fast
- Non-invasive
- Easy-to-use
Test at any location, review
results on the device or online
- Hospital
- Cancer Center
- Outpatient Clinic
- Physician Office
- Rehabilitation
- Radiology
Resources
SOZO Digital Health Platform
SOZO uses ImpediMed’s BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. SOZO is non-invasive, fast, and easy to use. Results from the 30-second test1 are available immediately providing proactive patient care including early detection of disease progression, treatment monitoring, and patient education.
References
- As tested on Android.